Aduro Biotech, Inc. (NASDAQ:ADRO) – Equities research analysts at Leerink Swann increased their Q3 2017 EPS estimates for shares of Aduro Biotech in a research note issued on Thursday. Leerink Swann analyst S. Fernandez now forecasts that the biotechnology company will post earnings per share of ($0.41) for the quarter, up from their prior forecast of ($0.43). Leerink Swann also issued estimates for Aduro Biotech’s Q4 2017 earnings at ($0.50) EPS, FY2017 earnings at ($1.51) EPS, FY2018 earnings at ($1.26) EPS, FY2019 earnings at ($0.78) EPS and FY2020 earnings at ($1.11) EPS.

Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.02. The firm had revenue of $5.90 million for the quarter, compared to the consensus estimate of $3.98 million. Aduro Biotech had a negative net margin of 609.58% and a negative return on equity of 43.92%. The company’s revenue was down 84.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.03 EPS.

WARNING: “Q3 2017 EPS Estimates for Aduro Biotech, Inc. Raised by Leerink Swann (ADRO)” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/07/q3-2017-eps-estimates-for-aduro-biotech-inc-raised-by-leerink-swann-adro.html.

ADRO has been the subject of a number of other research reports. BidaskClub upgraded Aduro Biotech from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Zacks Investment Research upgraded Aduro Biotech from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research note on Tuesday, July 4th. Rodman & Renshaw initiated coverage on Aduro Biotech in a research note on Monday, May 1st. They issued a “buy” rating and a $18.00 target price for the company. Cowen and Company initiated coverage on Aduro Biotech in a research note on Tuesday, July 18th. They issued an “outperform” rating for the company. Finally, Canaccord Genuity set a $30.00 target price on Aduro Biotech and gave the company a “buy” rating in a research note on Thursday. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $19.00.

Shares of Aduro Biotech (NASDAQ ADRO) opened at 12.25 on Monday. The stock’s 50 day moving average price is $12.14 and its 200 day moving average price is $10.93. Aduro Biotech has a 12-month low of $8.75 and a 12-month high of $16.43. The company’s market cap is $902.53 million.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Blair William & Co. IL raised its position in Aduro Biotech by 0.4% in the first quarter. Blair William & Co. IL now owns 189,790 shares of the biotechnology company’s stock worth $2,135,000 after buying an additional 735 shares during the period. Legal & General Group Plc raised its position in Aduro Biotech by 11.2% in the second quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock worth $118,000 after buying an additional 1,043 shares during the period. American International Group Inc. raised its position in Aduro Biotech by 7.1% in the first quarter. American International Group Inc. now owns 21,840 shares of the biotechnology company’s stock worth $235,000 after buying an additional 1,447 shares during the period. Parametric Portfolio Associates LLC raised its position in Aduro Biotech by 15.9% in the first quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock worth $166,000 after buying an additional 2,119 shares during the period. Finally, Tudor Investment Corp ET AL raised its position in Aduro Biotech by 34.8% in the first quarter. Tudor Investment Corp ET AL now owns 15,436 shares of the biotechnology company’s stock worth $166,000 after buying an additional 3,984 shares during the period. 35.60% of the stock is owned by institutional investors.

In related news, insider Stephen T. Isaacs sold 27,273 shares of the firm’s stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $10.01, for a total transaction of $273,002.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Thomas W. Dubensky sold 5,699 shares of the firm’s stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $9.92, for a total value of $56,534.08. Following the transaction, the insider now directly owns 41,300 shares of the company’s stock, valued at approximately $409,696. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 419,205 shares of company stock valued at $4,410,591. 6.60% of the stock is owned by corporate insiders.

Aduro Biotech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Earnings History and Estimates for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.